Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

✍ Scribed by E. Bajetta; L.Y. Dirix; L.E. Fein; S.E. Jones; J. Cervek; M. Kaufmann; C. Fowst; A. Polli; E. di Salle; G. Massimini

• Book ID: 117667255
• Publisher: Elsevier Science
• Year: 1999
• Tongue: English
• Weight: 110 KB
• Volume: 35
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(99)80705-9